TAS
RYTM icon

TIFF Advisory Services’s Rhythm Pharmaceuticals RYTM Stock Holding History

TIFF Advisory Services’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,174
Closed -$217K – 13
2019
Q1 		$217K Buy
+7,174
New +$206K 0.09% 12

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TIFF Advisory Services's RYTM Position: Q2 2019 in Review

TIFF Advisory Services sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2019, closing a stake of 7,174 shares — an estimated $217K sold.

TIFF Advisory Services first reported a position in RYTM in Q1 2019 and held it in 1 quarter. The position peaked at $217K in Q1 2019. 84 funds tracked by Wall St. Rank hold RYTM as of Q2 2019.

  • TIFF Advisory Services reported no remaining Rhythm Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • TIFF Advisory Services sold 7,174 Rhythm Pharmaceuticals shares in Q2 2019, an estimated $217K.
  • TIFF Advisory Services first reported a position in Rhythm Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • TIFF Advisory Services's Rhythm Pharmaceuticals position peaked at $217K in Q1 2019.
  • 84 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2019.

Based on TIFF Advisory Services's 13F filing for Q2 2019, filed 12 Aug 2019.